Published in Cancer Weekly, June 21st, 2005
Earlier analyses showed that the addition of Genasense to chemotherapy yielded a statistically significant increase in overall response, complete response, and time-to-progression. Extended follow-up for a minimum of 24 months in all patients has revealed that patients treated with Genasense also achieved a significant increase in "durable" response (i.e., responses longer than 6 months duration) (p=0.02) and a near-significant trend toward increased overall survival (p=0.077).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.